The Company reported positive results of a Phase I/IIa clinical trial from its lead product PAC-113, an antifungal. These results show PAC-113 is generally safe, well-tolerated, and active in the treatment of oral Candida infection with clinical cure rates comparable to the current standard of care. A Phase IIb study in patients with oral Candidiasis, to establish additional efficacy, safety data as well as determine the optimize dose and formulation of PAC-113 was initiated in November 2007. The Company expect to receive the results for this Phase IIb study in mid 2008.
Pacgen also has an early stage research program. The most advanced of three candidates is a peptide therapeutic, PAC-G31P, which is currently being investigated in preclinical studies for its potential to treat inflammatory disease.
